A multicenter study of DDAVP versus platelet transfusions for antiplatelet agent reversal in patients with traumatic brain injury
Neurological Sciences · 2024
DOI: 10.1007/s10072-024-07379-x ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Neurological Sciences, 2024. Verfasst von Kristen M Westfall und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Trinity Health Ann Arbor, Ann Arbor, MI, USA. Kristen.Westfall@trinity-health.org. Hauptthemen laut MEDLINE: Brain Injuries, Traumatic, Platelet Aggregation Inhibitors, Platelet Transfusion, Deamino Arginine Vasopressin. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Antiplatelet agents have been shown to worsen outcomes following traumatic injury. Research on desmopressin (DDAVP) and platelet transfusion for antiplatelet reversal is limited. We aimed to evaluate the effect of these agents on patients taking pre-injury antiplatelet medications who experienced traumatic brain injury (TBI) after blunt trauma. METHODS: This is a retrospective cohort study of adult trauma patients from 2014 to 2021 on aspirin and/or a P2Y12 inhibitor. Patients were stratified into groups based on if they received DDAVP, platelets, both agents, or neither. RESULTS: Of 5525 included patients, 4696 (85.4%) were not reversed, 461 (8.4%) received platelets, 173 (3.1%) received DDAVP, and 172 (3.1%) received both reversals. There was no statistically significant difference in length of stay between, but patients who received platelets or both reversals were more likely to have hospital complications (p < 0.05), longer hospital length of stay (p < 0.001), and longer ICU length of stay (p < 0.001) compared to those who did not receive reversal. A subgroup analysis of patients with a head AIS of 4 or 5 confirmed these findings. CONCLUSIONS: Patients who received platelets or both reversals had a longer length of hospital stay and length of ICU stay. It is difficult to recommend one treatment over another based on our results alone. Further studies are needed to help clarify the risks and benefits of reversal agents in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Trinity Health Ann Arbor, Ann Arbor, MI, USA. Kristen.Westfall@trinity-health.org.
- Department of Pharmacy, Trinity Health Ann Arbor, Ann Arbor, MI, USA.
- Department of Surgery, Trinity Health Ann Arbor, Ann Arbor, MI, USA.
Zitieren
APA
Westfall, K. M., Andrews, J., Sadek, E., Curtiss, W., & Hecht, J. (2024). A multicenter study of DDAVP versus platelet transfusions for antiplatelet agent reversal in patients with traumatic brain injury. Neurological Sciences. https://doi.org/10.1007/s10072-024-07379-x
Vancouver
Westfall KM, Andrews J, Sadek E, Curtiss W, Hecht J. A multicenter study of DDAVP versus platelet transfusions for antiplatelet agent reversal in patients with traumatic brain injury. Neurological Sciences. 2024. doi:10.1007/s10072-024-07379-x
BibTeX
@article{Westfall2024,
author = {Westfall, Kristen M and Andrews, Jessica and Sadek, Erin and Curtiss, William and Hecht, Jason},
title = {A multicenter study of DDAVP versus platelet transfusions for antiplatelet agent reversal in patients with traumatic brain injury},
journal = {Neurological Sciences},
year = {2024},
doi = {10.1007/s10072-024-07379-x}
}
EUVIMED